Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Comment
. 2025 Jun 30:10:9.
doi: 10.21037/aes-25-2.

Janus kinase inhibitors: another potential for uveitis treatment?

Seema Emami  1 , Eirini Kaisari  1 , Timothy M Janetos  1
Affiliations
Comment

Janus kinase inhibitors: another potential for uveitis treatment?

Seema Emami et al. Ann Eye Sci. .
No abstract available

Keywords: Janus kinase inhibitors (JAKi); Uveitis; cystoid macular edema.

PubMed Disclaimer

Conflict of interest statement

Conflicts of Interest: All authors have completed the ICMJE uniform disclosure form (available at https://aes.amegroups.com/article/view/10.21037/aes-25-2/coif). T.M.J. serves as an unpaid editorial board member of Annals of Eye Science from November 2024 to December 2026. The other authors have no conflicts of interest to declare.

Comment on

  • Filgotinib in Active Noninfectious Uveitis: The HUMBOLDT Randomized Clinical Trial.
    Srivastava SK, Watkins TR, Nguyen QD, Sharma S, Scales DK, Dacey MS, Shah RE, Chu DS, Grewal DS, Faia LJ, Suhler EB, Genovese MC, Guo Y, Barchuk WT, Besuyen R, Dick AD, Rosenbaum JT. Srivastava SK, et al. JAMA Ophthalmol. 2024 Sep 1;142(9):789-797. doi: 10.1001/jamaophthalmol.2024.2439. JAMA Ophthalmol. 2024. PMID: 39023880 Free PMC article. Clinical Trial.

References

    1. Srivastava SK, Watkins TR, Nguyen QD, et al. Filgotinib in Active Noninfectious Uveitis: The HUMBOLDT Randomized Clinical Trial. JAMA Ophthalmol 2024;142:789–97. - PMC - PubMed
    1. Benucci M, Bernardini P, Coccia C, et al. JAK inhibitors and autoimmune rheumatic diseases. Autoimmun Rev 2023;22:103276. - PubMed
    1. Pandey R, Bakay M, Hakonarson H. SOCS-JAK-STAT inhibitors and SOCS mimetics as treatment options for autoimmune uveitis, psoriasis, lupus, and autoimmune encephalitis. Front Immunol 2023;14:1271102. - PMC - PubMed
    1. Angelini J, Talotta R, Roncato R, et al. JAK-Inhibitors for the Treatment of Rheumatoid Arthritis: A Focus on the Present and an Outlook on the Future. Biomolecules 2020;10:1002. - PMC - PubMed
    1. Vitale A, Palacios-Olid J, Caggiano V, et al. Efficacy and safety of Janus kinase inhibitors in non-infectious inflammatory ocular diseases: a prospective cohort study from the international AIDA network registries. Front Med (Lausanne) 2024;11:1439338. - PMC - PubMed

LinkOut - more resources